Subtype
Colorectal Carcinoma
CI-CAN-00005005CRCExplore in graph →
344 active trials5 approved drugs22 evidence items
- NCIt
- C2955
Loading cancer entity…
Subtype
CI-CAN-00005005CRCExplore in graph →
Clinical trials
1,010 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (127)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03601598 | A Trial of SHR-1210 in Combination With SHR6390 in Patients With Advanced CRC, NSCLC and HCC | unknown | Phase 1 / Phase 2 | 41 | Harbin Medical UniversityOTHER | 0 | Jul 26, 2018 | clinicaltrials |
| NCT02423954 | Study of Nivolumab Plus Chemotherapy in Patients With Advanced Cancer (NivoPlus)(NivoPlus) | terminated | Phase 1 / Phase 2 | 33 | Western Regional Medical CenterOTHER | 1 | Jul 2, 2018 |
| NCT02638909 | Study of Oral Ceritinib in Patients With ALK and ROS1 Activated Gastrointestinal Malignancies | terminated | Phase 2 | 4 | Criterium, Inc.INDUSTRY | 1 | Apr 2, 2018 | clinicaltrials |
| NCT01462513 | L-BLP25 in Patients With Colorectal Carcinoma After Curative Resection of Hepatic Metastases(LICC) | completed | Phase 2 | 122 | Prof. Dr. Carl SchimanskiOTHER | 2 | Feb 13, 2018 | clinicaltrials |
| NCT02119676 | Study of Ruxolitinib in Colorectal Cancer Patients | terminated | Phase 2 | 396 | Incyte CorporationINDUSTRY | 8 | Feb 13, 2018 | clinicaltrials |
| NCT01729923 | A Trial of Maintenance ADAPT Therapy With Capecitabine and Celecoxib in Patients With Metastatic Colorectal Cancer(ADAPT) | terminated | Phase 2 | 27 | University of WashingtonOTHER | 1 | Jan 16, 2018 | clinicaltrials |
| NCT01139138 | Safety Study of the Combination of Panitumumab, Irinotecan and Everolimus in the Treatment of Advanced Colorectal Cancer(PIE) | completed | Phase 1 / Phase 2 | 49 | The Queen Elizabeth HospitalOTHER | 1 | Nov 6, 2017 | clinicaltrials |
| NCT01606124 | Polyphenon E in Treating Patients With High-Risk of Colorectal Cancer | terminated | Phase 2 | 39 | Mayo ClinicOTHER | 1 | Oct 27, 2017 | clinicaltrials |
| NCT01348256 | Study With Dendritic Cell Immunotherapy in Resected Hepatic Metastasis of Colorectal Carcinoma | unknown | Phase 2 | 58 | Clinica Universidad de Navarra, Universidad de NavarraOTHER | 1 | Oct 24, 2017 | clinicaltrials |
| NCT00682786 | Genotype-directed Neoadjuvant Chemoradiation for Rectal Carcinoma | completed | Phase 2 | 135 | Washington University School of MedicineOTHER | 1 | Oct 6, 2017 | clinicaltrials |
| NCT01333709 | Multicenter Phase 2 Trial: a Tailored Strategy for Locally Advanced Rectal Carcinoma(GRECCAR4) | completed | Phase 2 | 150 | Institut du Cancer de Montpellier - Val d'AurelleOTHER | 1 | Aug 21, 2017 | clinicaltrials |
| NCT01095523 | Prospective Randomized Trial Evaluating Mandatory Second Look Surgery With HIPEC and CRS vs. Standard of Care in Subjects at High Risk of Developing Colorectal Peritoneal Metastases | withdrawn | Phase 2 | 0 | National Cancer Institute (NCI)NIH | 1 | Jul 2, 2017 | clinicaltrials |
| NCT00582660 | Evaluation of Surgically Resected Colorectal Adenomas and Carcinomas After 7 Days Pretreatment With Celecoxib(UAB0040) | completed | Phase 2 | 40 | University of Alabama at BirminghamOTHER | 1 | Jun 15, 2017 | clinicaltrials |
| NCT00307736 | Bevacizumab, Erlotinib and 5-Fluorouracil With External Beam Radiation Therapy in Locally Advanced Rectal Cancer | completed | Phase 1 / Phase 2 | 32 | Massachusetts General HospitalOTHER | 1 | May 10, 2017 | clinicaltrials |
| NCT01646554 | Efficacy of FOLFOX Versus FOLFOX Plus Aflibercept in K-ras Mutant Patients With Resectable Liver Metastases(BOS3) | withdrawn | Phase 2 / Phase 3 | 0 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 0 | May 9, 2017 | clinicaltrials |
| NCT00828984 | Macrogol 3350-based Oral Osmotic Laxative in Preventing Cancer in Patients at Risk of Colorectal Cancer | completed | Phase 2 | 87 | National Cancer Institute (NCI)NIH | 1 | Apr 18, 2017 | clinicaltrials |
| NCT02413853 | Combination Chemotherapy and Bevacizumab With or Without PRI-724 in Treating Patients With Newly Diagnosed Metastatic Colorectal Cancer(PRIMIER) | withdrawn | Phase 2 | 0 | University of Southern CaliforniaOTHER | 1 | Apr 17, 2017 | clinicaltrials |
| NCT01270438 | Combination Chemotherapy and Bevacizumab With or Without RO4929097 in Treating Patients With Metastatic Colorectal Cancer | withdrawn | Phase 2 | 0 | National Cancer Institute (NCI)NIH | 1 | Apr 4, 2017 | clinicaltrials |
| NCT00361244 | SU011248 in Combination With Irinotecan and Cetuximab as a Second Line Regimen for Stage IV Colorectal Cancer | terminated | Phase 1 / Phase 2 | 6 | Massachusetts General HospitalOTHER | 1 | Feb 17, 2017 | clinicaltrials |
| NCT02046538 | Phase II Study of Zaltrap and Chemotherapy for Advanced Resectable Colorectal Cancer | withdrawn | Phase 2 | 0 | Weill Medical College of Cornell UniversityOTHER | 1 | Jan 25, 2017 | clinicaltrials |
| NCT02617134 | CAR-T Cell Immunotherapy in MUC1 Positive Solid Tumor | unknown | Phase 1 / Phase 2 | 20 | PersonGen BioTherapeutics (Suzhou) Co., Ltd.INDUSTRY | 1 | Dec 6, 2016 | clinicaltrials |
| NCT02839954 | CAR-pNK Cell Immunotherapy in MUC1 Positive Relapsed or Refractory Solid Tumor | unknown | Phase 1 / Phase 2 | 10 | PersonGen BioTherapeutics (Suzhou) Co., Ltd.INDUSTRY | 1 | Dec 6, 2016 | clinicaltrials |
| NCT00362102 | A Phase II Study of Cetuximab Plus Irinotecan in Patients With EGFR-detectable Metastatic Colorectal Carcinoma | completed | Phase 2 | 38 | Eli Lilly and CompanyINDUSTRY | 0 | Nov 22, 2016 | clinicaltrials |
| NCT02287727 | Regorafenib in Reducing Recurrence in Patients With Non-metastatic Rectal Cancer Who Have Completed Curative-Intent Treatment | withdrawn | Phase 2 | 0 | Roswell Park Cancer InstituteOTHER | 1 | Oct 12, 2016 | clinicaltrials |
| NCT01937715 | A Study Of PF-05212384 Plus FOLFIRI Versus Bevacizumab Plus FOLFIRI In Metastatic Colorectal Cancer | terminated | Phase 1 / Phase 2 | 18 | PfizerINDUSTRY | 3 | Aug 18, 2016 | clinicaltrials |
| NCT00336856 | Irinotecan and Cetuximab for Colorectal Cancer as Second Line Therapy | completed | Phase 2 | 35 | University of PittsburghOTHER | 1 | Jul 12, 2016 | clinicaltrials |
| NCT01111292 | Inositol in Preventing Colorectal Cancer in Patients With Colitis-Associated Dysplasia | terminated | Phase 1 / Phase 2 | 5 | National Cancer Institute (NCI)NIH | 1 | Jul 12, 2016 | clinicaltrials |
| NCT02575508 | Pan FGFR Kinase Inhibitor BGJ398 and Combination Chemotherapy in Treating Patients With Untreated Metastatic Pancreatic Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Roswell Park Cancer InstituteOTHER | 1 | May 20, 2016 | clinicaltrials |
| NCT01483638 | Axitinib as Maintenance Treatment in Patients With Metastatic CRC(TTD-11-01) | terminated | Phase 2 | 84 | Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)OTHER | 1 | May 12, 2016 | clinicaltrials |
| NCT01675128 | ISIS 183750 With Irinotecan for Advanced Solid Tumors or Colorectal Cancer | completed | Phase 1 / Phase 2 | 24 | National Cancer Institute (NCI)NIH | 1 | Apr 25, 2016 | clinicaltrials |
| NCT01157039 | A Trial of Glutamine to Prevent Oxaliplatin Neurotoxicity and a Pharmacokinetic Analysis of Oxaliplatin | withdrawn | Phase 2 | 0 | AHS Cancer Control AlbertaOTHER | 0 | Feb 24, 2016 | clinicaltrials |
| NCT01856322 | Surgery Plus Sulindac or Surgery Alone for Advanced Colorectal Cancer | terminated | Phase 2 | 3 | National Cancer Institute (NCI)NIH | 1 | Oct 23, 2015 | clinicaltrials |
| NCT01703910 | Study of Individualized Therapies Selection for Patients With Metastatic Colorectal Carcinoma According to the Therapeutic | completed | Phase 2 | 29 | Centro Nacional de Investigaciones Oncologicas CARLOS IIIOTHER | 1 | Oct 9, 2015 | clinicaltrials |
| NCT00100841 | Phase II Trial of FOLFOX6, Bevacizumab and Cetuximab in Patients With Colorectal Cancer | completed | Phase 2 | 66 | National Cancer Institute (NCI)NIH | 1 | Jul 27, 2015 | clinicaltrials |
| NCT00735241 | FOLFOX6 Plus Sir-Spheres Microspheres Plus Avastin in Patients With Nonresectable Liver Metastases From Colorectal Carcinoma(FAST) | withdrawn | Phase 2 / Phase 3 | 0 | Sirtex MedicalINDUSTRY | 1 | May 22, 2015 | clinicaltrials |
| NCT02235324 | Ziv-Aflibercept Followed by Ziv-Aflibercept, Fluorouracil, and Leucovorin Calcium in Treating Patients With Stage IV Colorectal Cancer | withdrawn | Phase 2 | 0 | University of Southern CaliforniaOTHER | 1 | May 6, 2015 | clinicaltrials |
| NCT02423226 | Computed Tomography-guided Brachytherapy Plus Chemotherapy for Locally Recurrent Rectum Cancer | completed | Phase 2 | 56 | The First People's Hospital of ChangzhouOTHER | 0 | Apr 22, 2015 | clinicaltrials |
| NCT00032110 | Erlotinib in Treating Patients With Recurrent or Metastatic Colorectal Cancer | completed | Phase 2 | 30 | National Cancer Institute (NCI)NIH | 1 | Apr 15, 2015 | clinicaltrials |
| NCT01277406 | 4SC-201 (Resminostat) in Advanced Colorectal Carcinoma(SHORE) | completed | Phase 1 / Phase 2 | 17 | 4SC AGINDUSTRY | 1 | Apr 1, 2015 | clinicaltrials |
| NCT00551421 | Pertuzumab and Cetuximab in Treating Patients With Previously Treated Locally Advanced or Metastatic Colorectal Cancer | completed | Phase 1 / Phase 2 | 17 | National Cancer Institute (NCI)NIH | 1 | Mar 31, 2015 | clinicaltrials |
| NCT02376452 | Phase II Study of 2-weekly RAILIRI Versus FOLFIRI as Second-line Treatment in Advanced Colorectal Cancer Patients | unknown | Phase 2 | 100 | Fudan UniversityOTHER | 1 | Mar 3, 2015 | clinicaltrials |
| NCT00704600 | Nelfinavir, a Phase I/Phase II Rectal Cancer Study(Nelfinavir) | completed | Phase 1 / Phase 2 | 15 | Maastricht Radiation OncologyOTHER | 1 | Dec 8, 2014 | clinicaltrials |
| NCT01554059 | Neoadjuvant Chemoradiation With Bevacizumab for Chinese Rectal Cancer Patients(New Beat) | completed | Phase 2 | 25 | Sixth Affiliated Hospital, Sun Yat-sen UniversityOTHER | 1 | Nov 10, 2014 | clinicaltrials |
| NCT02268006 | IMRT-SIB and Capecitabine in Preoperative Rectal Cancer Treatment(BISER) | unknown | Phase 2 | 50 | Institute of Oncology LjubljanaOTHER | 1 | Oct 20, 2014 | clinicaltrials |
| NCT01418742 | SKIP - A Double-blind Placebo-controlled Randomized Multicenter Trial of Skin Toxicity Treatment | terminated | Phase 2 | 11 | Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbHOTHER | 1 | Jul 14, 2014 | clinicaltrials |
| NCT00942266 | Vorinostat, Fluorouracil, and Leucovorin Calcium in Treating Patients With Metastatic Colorectal Cancer That Has Not Responded to Previous Treatment | completed | Phase 2 | 58 | Roswell Park Cancer InstituteOTHER | 1 | Jun 23, 2014 | clinicaltrials |
| NCT01208194 | Efficacy Study of a Maintenance Therapy With Immunomodulator MGN1703 in Patients With Advanced Colorectal Carcinoma(IMPACT) | completed | Phase 2 | 59 | Mologen AGINDUSTRY | 6 | Jun 20, 2014 | clinicaltrials |
| NCT00862784 | A Study of IMC-1121B (Ramucirumab) in Colorectal Cancer | completed | Phase 2 | 48 | Eli Lilly and CompanyINDUSTRY | 2 | Jun 17, 2014 | clinicaltrials |
| NCT00909987 | Study of Neoadjuvant CT With Selective Radiotherapy in Patients With Intermediate-Risk Cancer Rectum | completed | Phase 2 | 46 | Grupo Espanol Multidisciplinario del Cancer DigestivoOTHER | 1 | Oct 11, 2013 | clinicaltrials |
| NCT00026234 | Hepatic Arterial Infusion Plus Chemotherapy in Treating Patients With Colorectal Cancer Metastatic to the Liver | completed | Phase 2 | 75 | National Cancer Institute (NCI)NIH | 1 | Jul 16, 2013 | clinicaltrials |
Data updated 22 days agoSource updated Jul 26, 2018source: clinicaltrials